Beyond GLP-1: researchers test a new approach to weight loss

The scientists who helped develop the GLP-1 drug class are now questioning one of its core assumptions. A new experimental approach - targeting GIP and glucagon receptors while skipping the GLP-1 receptor entirely - may produce comparable weight loss with fewer of the side effects that cause so many patients to reduce their dose or stop treatment altogether.

Who is behind this research

The work comes from Richard DiMarchi and Matthias Tschöp, two researchers with direct roles in the development of the incretin drug class that produced GLP-1 medications as we know them today. DiMarchi led the chemistry behind tirzepatide's dual GIP/GLP-1 design. Tschöp has spent decades at the intersection of metabolic hormones and obesity science.

Their new paper, published as a peer-reviewed draft in Molecular Metabolism and funded by BlueWater Biosciences, proposes that the GLP-1 receptor may not be necessary for effective obesity treatment - and that targeting GIP and glucagon receptors alone, at high doses, could produce results comparable to approved GLP-1 medications.

That's a direct challenge to the foundational assumption of the entire current generation of obesity drugs.

Why the GLP-1 receptor might not be the essential ingredient

To understand the argument, it helps to know how the current drugs work.

Semaglutide (Ozempic, Wegovy) targets the GLP-1 receptor only. It mimics the hormone glucagon-like peptide-1, which is released by the gut after eating and signals satiety to the brain, slows gastric emptying, and reduces appetite.

Tirzepatide (Mounjaro, Zepbound) adds a second target - the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone with metabolic and appetite-modulating effects. Activating both receptors simultaneously is why tirzepatide produces roughly 20% average weight loss compared to semaglutide's roughly 14% in the SURMOUNT-5 head-to-head trial.

The experimental molecule from DiMarchi and Tschöp goes further. It activates GIP and glucagon receptors but omits the GLP-1 receptor entirely. Glucagon is primarily known as a hormone that raises blood glucose - the opposite of what you'd want in a metabolic treatment. But at controlled doses, glucagon also stimulates fat burning, increases energy expenditure, and suppresses appetite through different pathways than GLP-1.

The hypothesis is that combining high-dose GIP and glucagon activation produces the metabolic and appetite-suppressing effects of GLP-1 treatments - but through mechanisms that carry a different, potentially more tolerable side effect profile.

The nausea problem with current GLP-1 medications

Nausea is the most commonly reported GLP-1 side effect and the most common reason patients reduce their dose or discontinue treatment. In the STEP 1 trial, nausea affected approximately 44% of participants on semaglutide 2.4mg at some point during the 68-week study. In SURMOUNT-1, tirzepatide produced nausea in roughly 30–33% of participants depending on dose.

Most of this nausea is driven by the GLP-1 receptor's effect on gastric motility - slowing stomach emptying, which produces the uncomfortable sensation of food sitting in the stomach for extended periods. This is the same mechanism that creates the satiety signal, which is why separating the two effects within the GLP-1 pathway has been difficult.

If you could achieve equivalent weight loss through GIP and glucagon pathways that don't rely on gastric slowing to the same degree, you might retain the metabolic benefit while reducing the tolerability burden. That's the core of DiMarchi and Tschöp's argument.

What the animal data actually shows

In rodent and monkey studies, the experimental dual GIP/glucagon molecule produced weight loss results that the researchers describe as comparable to approved GLP-1 treatments. The animals showed reduced food intake, decreased body fat, and improved metabolic markers - with the researchers reporting fewer gastrointestinal side effects compared to GLP-1 receptor activation.

These are genuinely interesting results. But they need to be held at arm's length for now. Animal models of obesity and metabolic disease have a poor track record of predicting human outcomes. The GLP-1 field itself is full of molecules that performed well in rodents and failed in human trials - Pfizer's danuglipron, for example, showed promising pre-clinical results before development was halted due to liver enzyme elevations in human studies.

The researchers acknowledge this directly. The paper presents a hypothesis and pre-clinical evidence, not a clinical breakthrough. No human trials have been published. The BlueWater Biosciences funding means there's a commercial interest in the approach, which is worth noting when evaluating the claims.

How this fits the broader direction of obesity science

The GIP/glucagon approach is one of several directions the field is exploring in parallel. The pattern across the entire next-generation drug pipeline is adding receptor targets to get more potent, more targeted metabolic effects:

• Tirzepatide - GLP-1 + GIP (approved, producing ~20% weight loss)
• Retatrutide - GLP-1 + GIP + glucagon triple agonist (Phase 3 complete, ~28% weight loss in TRIUMPH-1)
• CagriSema - GLP-1 + amylin (REIMAGINE Phase 3 data positive, FDA decision Q4 2026)
• DiMarchi/Tschöp molecule - GIP + glucagon only, no GLP-1 (pre-clinical only)

The interesting thing about the DiMarchi/Tschöp work is that it goes in a different direction from the rest of the pipeline - removing GLP-1 rather than adding more targets on top of it. It challenges the assumption that GLP-1 activation is the indispensable core of effective obesity pharmacotherapy.

If the approach holds up in human trials, it could eventually matter for the large proportion of patients who experience intolerable GLP-1 side effects - particularly severe nausea, vomiting, or gastroparesis-like symptoms that currently lead to dose reduction or discontinuation. A non-GLP-1 route to comparable weight loss would be a meaningful addition to the treatment toolkit.

What this means for people on GLP-1 medications now

Practically speaking, this research doesn't change anything for your current treatment. No GIP/glucagon-only drug is anywhere near clinical availability. The earliest a human trial could produce usable data is several years away, and that's assuming the molecule performs comparably in humans - which is far from guaranteed.

What this research does signal is that the scientific community is actively interrogating the limits of the GLP-1 mechanism and looking for alternatives or complements - partly because of the tolerability problems that affect a meaningful minority of patients.

If you're one of the people who struggles with nausea on semaglutide or tirzepatide, the most practical options right now are still within the existing framework: slower dose titration, eating smaller and lower-fat meals, taking the medication at a consistent time, and identifying which foods trigger the worst symptoms for you specifically. The new generation of drugs may eventually offer different options, but that timeline is measured in years, not months.

The nutritional picture across all these drug types

One thing that doesn't change regardless of which receptor a drug targets is the basic consequence of eating less. GLP-1 medications, tirzepatide, and whatever comes next all work by reducing food intake - and reduced food intake means reduced micronutrient absorption.

Nausea-related restrictions compound this. When nausea is a factor, many patients default to bland, lower-nutrient foods that are easier to tolerate - crackers, plain rice, broth - and away from the vegetables, proteins, and diverse whole foods that carry the vitamins and minerals their bodies still need.

A 2026 meta-analysis of nearly 480,825 adults on GLP-1 medications found 13.6% rates of vitamin D deficiency, 64% insufficient iron, and elevated rates of vitamin B12 deficiency. These gaps don't resolve on their own when nausea improves. Targeted supplementation is the most reliable way to close them. GLP-1 Shield is formulated specifically for this purpose - addressing the micronutrient depletion that current and next-generation weight loss drugs consistently produce.

Frequently asked questions

Is there a weight loss drug that works without causing nausea?

Not yet available, but researchers are working on it. A pre-clinical study published in Molecular Metabolism by scientists Richard DiMarchi and Matthias Tschöp proposes a GIP/glucagon-only approach that may produce comparable weight loss to GLP-1 medications with fewer gastrointestinal side effects. This is still in animal studies only - no human trial data exists yet.

Why do GLP-1 medications cause nausea?

GLP-1 receptor activation slows gastric emptying - the rate at which your stomach empties into the small intestine. This creates the satiety signal but also produces nausea in many patients, particularly during dose escalation. Approximately 30–44% of patients in major trials reported nausea at some point during treatment, though it often improves after the first few weeks at each dose level.

What is the difference between GLP-1, GIP, and glucagon receptors?

GLP-1 (glucagon-like peptide-1) reduces appetite and slows gastric emptying. GIP (glucose-dependent insulinotropic polypeptide) enhances insulin secretion and has metabolic and appetite effects that complement GLP-1. Glucagon raises blood glucose but also stimulates fat burning and energy expenditure. Tirzepatide targets GLP-1 and GIP together. Retatrutide targets all three. The new experimental drug targets GIP and glucagon but not GLP-1.

When will non-GLP-1 weight loss drugs be available?

The GIP/glucagon approach from DiMarchi and Tschöp is pre-clinical only - no human trials have been published. Realistically, even if Phase 1 trials begin in 2026, a path to approval would take a minimum of 5–7 years assuming positive results at each stage. Other next-generation options like retatrutide and CagriSema are much closer to clinical availability.